Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2005-08-03
2009-11-03
Nickol, Gary B (Department: 1648)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
07612173
ABSTRACT:
This invention relates to novel HIV polypeptide and polynucleotide fusions of Gag, Pol and Nef which are useful in immunogenic compositions and vaccines. The invention relates in particular to a polypeptide which comprises Nef or an immunogenic fragment thereof, and p17 Gag and/or p24 Gag or immunogenic fragments thereof, wherein when both p17 and p24 Gag are present there is at least one HIV antigen or immunogenic fragment between them. The polypeptide may also comprise Pol or RT or an immunogenic fragment thereof.
REFERENCES:
patent: 5221610 (1993-06-01), Montagnier et al.
patent: 5962635 (1999-10-01), Azad et al.
patent: 2003/0108562 (2003-06-01), Hanke et al.
patent: 2003/0190308 (2003-10-01), Braun et al.
patent: 2004/0073008 (2004-04-01), Iglesias Perez et al.
patent: 2005/0175627 (2005-08-01), Schneider
patent: 0577894 (1994-12-01), None
patent: 115596 (2006-06-01), None
patent: 01/43693 (2001-06-01), None
patent: 02/22080 (2002-03-01), None
patent: 02/068654 (2002-09-01), None
patent: 03/025003 (2003-03-01), None
patent: 2004/041851 (2004-05-01), None
patent: 2004/041852 (2004-05-01), None
patent: 2005/030964 (2005-04-01), None
Woodberry et al., Immunogenicity of a Human Immunodeficiency Virus (HIV) Polytope Vaccine Containing Multiple HLA A2 HIV CD81 Cytotoxic T-Cell Epitopes, Journal of Virology, Jul. 1999, 73(7): 5320-5325.
Vazquez-Blomquist et al., The HIV-1 chimeric protein CR3 expressed by poxviral vectors induces a diverse CD8+ T cell response in mice and is antigenic for PBMCs from HIV+ patients, Vaccine, 2003, 22:145-155.
Moore et al., The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1, Vaccine, 1999, 17:2517-2527.
Kong, et al., “Immunogenicity of Multiple Gene and Clade Human Immunodeficiency Virus Type 1 DNA Vaccines,” J. Virol. 77:12764-12772 (Dec. 2003).
Asjo et al., Phase I trial of a therapeutic HIV type 1 vaccine, Vacc-4x, in HIV type 1-infected individuals with or without antiretroviral therapy, AIDS Res Hum Retroviruses 18(18):1357-65 (Dec. 2002).
Azad et al., Large-scale production and characterization of recombinant HIV-1 Nef, J. General Virology, 75:651-655 (1994).
Berzofsky, Progress toward an artificial vaccine for HIV: identification of helper and cytotoxic T-cell epitopes and methods of immunization. Biotechnol. Ther. 2(1-2): 123-35 (1991).
Betts et al., Optimal antigens for HIV vaccines based on CD8+ T response, protein length, and sequence variability. DNA Cell Biology 21(9):665-70 (Sep. 2002).
Bodeus et al., In vitro binding and phosphorylation of HIV-1 Nef protein by serine/threonine protein kinase, J. General Virology, 76:1337-44 (1995).
Buck et al. The HIV-1 gag gene encodes an internal ribosome entry site, Journal of Virology 75(1):181-191 (2001).
Cosma et al., Therapeutic vaccination with MVA-HIV-1 nef elicits Nef-specific T-helper cell responses in chronically HIV-1 infected individuals. Vaccine 22(1)21-9 (Dec. 2003).
Dinchuk et al., Generation of transgenic mice carrying H IV TAT and NEF genes. (Abstract)Int Conf AIDS 1990 Jun. 20-23; 6:192(abstract No. Th.A.291).
Estaquier et al., Comprehensive delineation of antigenic and immunogenic properties of peptides derived from the nef HIV-1 regulatory protein. Vaccine 11(11):1083-92 (1993).
Gahery-Segard et al., Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine: characterization of CD8+-T-cell epitopes recognized. J. Virol. 77(20):11220-31 (Oct. 2003).
Gahery-Segard et al., Multiepitopic B- and T-cell responses induced in humans by a human immunodeficiency virus type 1 lipopeptide vaccine. J. Virol. 74(4):1694-703 (Feb. 2000).
Hinkula et al., Recognition of prominent viral epitopes induced by immunization with HIV-1 regulatory genes, J. Virology, 71:7 5528-39 (1997).
Iglesias et al. Chimeric proteins containing HIV1 T cell epitopes: expression inE. coli, purification and induction of antibodies in mice, J. Biochem Mol Bio & Biophys, 5:109-122 (2000).
Johnson and Walker. Cytotoxic T lymphocytes in human immunodeficiency virus infection: responses to structural proteins. Curr Top Microbiol Immuno1;189:35-63 (1994).
Kmieciak et al., Enhancement of cellular and humoral immune responses to human immunodeficiency virus type 1 Gag and Pol by a G/P-92 fusion protein expressing highly immunogenic Gag p17/p24 and Pol p51 antigens. J. Human Virology 4(6):306-16 (2001).
Letvin et a., Progress in the development of Nan HIV-1 vaccine, Science, 280:1875 (1998).
Menendez-Arias et al., Cytotoxic T-lymphocyte responses to HIV-1 reverse transcriptase (review). Viral Immunol 11(4) :167-81 (1998).
Miller and Sarver, HIV accessory proteins as therapeutic targets. Nat Med 3(4):389-94 (1997).
Moore et al. The adjuvant combination monophosphoryl lipid A and QS21 switches T cell responses induced with a soluble recombinant HIV protein from Th2 to Th1, Vaccine, 1999, 17:2517-2527 (1999).
Murphy et al., The HIV-1 regulatory protein Nef has a specific function in viral expression in a murine macrophage cell line. J. Leukocyte Biology 56:294-303 (Sep. 1994).
Partidos et al., The effect of orientation of peptides on the immunogenicity of chimeric synthetic peptides representing measles virus protein sequences, Molecular Immunology, 29(5):651-658 (1992).
Pialoux et al., Lipopeptides induce cell-mediated anti-HIV immune responses in seronegative volunteers. AIDS 15(10):1239-49 (Jul. 2001).
Robert-Guroff, HIV Regulatory and accessory proteins: new targets for vaccine development. DNA and Cell Biology. 21(9): 597-598. (Sep. 2002).
Ruprecht et al., 1999: a time to re-evaluate AIDS vaccine strategies. Journal of Hum. Virol. 3(2):88-93 (2000).
Shiver et al., Recent advances in the development of HIV-1 vaccines using replication-incompetent adenovirus vectors. Annual Rev Med. 55:355-72 (2004).
Abrecht Helge
Delchambre Martine
Marchand Martine
Mathy Nathalie Louise
Permanne Philippe Jean Gervais Ghislain
Campen Virginia G.
GlaxoSmithKline Biologicals s.a.
Kinsey White Nicole
Nickol Gary B
SmithKline Beecham Corporation-Corporate Intellectual Property-U
LandOfFree
Vaccine for prevention and treatment of HIV-infection does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Vaccine for prevention and treatment of HIV-infection, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Vaccine for prevention and treatment of HIV-infection will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4114166